SAN DIEGO, Jan. 20 /PRNewswire/ -- Immusol announced today that Clark F. Springgate, M.D., Ph.D. has joined its executive management team as Vice President of Clinical and Regulatory. Dr. Springgate will assume responsibility for the design, development and execution of all ongoing and future clinical programs and regulatory submissions.
"As Immusol advances its clinical programs and initiates other drug candidates into clinical testing, we are pleased to have a professional with Clark's breadth of knowledge and experience on our team," commented Dr. Tsvi Goldenberg, Immusol Chairman and CEO. "We look forward to his contributions as they further our clinical programs."
Previously, Dr. Springgate was Chief Medical Officer and Consultant for Glycogenesys in Boston where he directed Phase I-III oncology trials. He has consulted for the pharmaceutical and biotechnology industries on medical and US and international regulatory issues, design of clinical trials, product licensing and development and pharmacovigilance. Dr. Springgate directed and founded the Clinical Research Center at New Britain General Hospital in Connecticut, a Center that was responsible for over 100 state-of-the-art clinical trials in a variety of disciplines. Dr. Springgate held positions as Medical Director at Procter and Gamble and as Vice President of Professional Services at Scicor following serving as Medical Director and Attending Physician at Ochsner Foundation Hospital and Clinic and Assistant Professor in the Department of Microbiology and Immunology at Tulane Medical Center in New Orleans.
Dr. Springgate received a Ph.D. in Biochemistry from Boston College and an M.D. at the University of Miami School of Medicine. He is Board certified in Clinical Pathology and a Diplomate of the National Board of Medical Examiners.
Immusol is a privately-held San Diego based biopharmaceutical company engaged in discovery and development of novel therapies to treat human diseases. Immusol uses an integrated biology approach, starting with a proprietary drug discovery technology to discover therapeutic proteins and targets in the areas of cancer, viral infection, ophthalmology and neurodegenerative and metabolic diseases. Based on these discoveries, Immusol develops protein and small molecule based therapies alone or in collaboration with drug development partners. Immusol has several lead drug candidates in various stages of clinical and pre-clinical development.
CONTACT: Andrea Lynn, Marketing Manager of Immusol, +1-858-824-1100